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Locally Advanced Breast Cancer (LABC)
This topic was one of the main themes of ABC2 and refers 
to inoperable LABC without distant metastases. The panel 
agreed on the need for a pre-therapeutic biopsy to determine 
histology and tumor biology (estrogen receptor (ER), proges-
terone (PR), HER2, and proliferation). Given the high risk 
for distant metastasis, the panel unanimously opted for a 
 subtle staging work-up, including clinical history, physical ex-
amination, and extensive imaging before the start of therapy. 
The panelists agreed on systemic therapy and not surgery or 
radiotherapy as the first therapeutic choice in this setting. If 
the tumor remains inoperable after systemic treatment and 
radiotherapy, ‘palliative’ mastectomy should only be used in 
cases for which an overall improvement of quality of life can 
be expected. A multidisciplinary treatment approach was seen 
as indicated for the majority of LABC cases. After systemic 
therapy (with or without radiotherapy), surgery would still 
be possible in the majority of cases. This would usally consist 
of mastectomy plus axillary dissection, although in a small 
proportion of patients breast conserving therapy may be an 
option.
The different tumor-biological subtypes were then dis-
cussed separately. For triple-negative LABC, anthracycline- 
and taxane-based chemotherapy was considered optimal. In 
HER2-positive LABC, concurrent taxane and anti-HER2 
therapy is recommended and anthracyclines should be incor-
porated sequentially. In ER-positive LABC, anthracycline- 
and taxane-based chemotherapy as well as endocrine therapy 
were accepted as therapeutic options. In the discussion it was 
emphasized that the choice of chemotherapy vs. endocrine 
therapy as the primary treatment depends on the patient (e.g. 
menopausal status, performance status, comorbidities, and 
preference) as well as tumor (e.g. grade and biomarkers) 
characteristics.
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Introduction
The Advanced Breast Cancer Second International Con-
sensus Conference (ABC2) took place in Lisbon, Portugal, 
from 7–9 November 2013. More than 1,000 participants from 
71 countries attended the 2 days of state-of-the art lectures on 
locally advanced and metastatic breast cancer and the consen-
sus panel discussion. This article briefly summarizes the topics 
discussed at the public consensus meeting in Lisbon on Satur-
day morning – a more detailed discussion of the consensus 
and its conclusions in the light of the German guidelines will 
follow in the first issue of Breast Care in 2014. Under the 
chairmanship of Fatima Cardoso (Portugal), Alberto Costa 
(Italy), Larry Norton (USA) and Eric Winer (USA), 41 inter-
national and multidisciplinary panel members (table 1) dis-
cussed the ABC2 statements. These statements included new 
statements for ABC2, statements of the ABC1 consensus 
(2011) that, based on new evidence, needed some modifica-
tions, and last but not least ABC1 statements that were still 
considered valid and thus were not discussed again. Given the 
limited time available on the Saturday morning, the interna-
tional panel primarily discussed the new statements for 
ABC2. This report only briefly summarizes the results of the 
consensus discussion and voting in Lisbon. The final ABC2 
consensus with the final written version of the consensus 
statements and all modified ABC1 statements will be pub-
lished in the official consensus publication by Dr. Cardoso 
and her colleagues in early 2014.
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Special Situations
For inflammatory breast cancer, the same treatment rec-
ommendations as for non-inflammatory LABC hold true. In 
general, modified radical mastectomy is recommended, even 
in cases with good response to primary systemic therapy. Im-
mediate reconstruction is not recommended. Locoregional 
radiotherapy (chest wall and lymph nodes) is required.
In BRCA-associated triple-negative or endocrine-resistant 
metastatic breast cancer (MBC) with anthracycline and taxane 
pretreatment, platinum-based chemotherapy may be considered. 
In patients with liver metastases, it was pointed out in the 
discussion that local treatment was only being looked at in a 
highly selected series of patients. So far, no survival advantage 
was proven. Nevertheless, local therapy was considered an 
option for patients with liver metastases if no extra-hepatic 
metastases were present and the disease was well controlled 
by systemic therapy.
In case of malignant pleural effusions, after cytological 
confirmation of diagnosis, the need for systemic therapy was 
emphasized. Drainage is indicated in symptomatic cases and 
intrapleural administration of talc or drugs such as bleomycin 
or biological-response modifiers may be helpful. 
Chest Wall and Regional (Nodal) Recurrences
Chest wall and locoregional (nodal) recurrences were 
 considered as potentially curable diseases, but with the burden 
of a risk of metastasis. Therefore, before any therapeutic deci-
sion is made, distant metastases should be excluded by clinical 
examination and extensive imaging. If local treatment is not 
feasible, palliative therapy should be performed,  according to 
the principles that are valid in metastatic breast cancer. If 
 locoregional treatment seems to be successful, after radical sur-
gery and radiotherapy, ‘secondary’ adjuvant systemic therapy 
including chemotherapy should also be administered. Chemo-
therapy seems to be most effective in ER- negative disease.
Concluding the section of new statements, there was some 
discussion on definitions with regard to the term ‘visceral  crisis’ 
and ‘endocrine resistance’, both often used in the literature 
aimed at stratification for treatment approaches. For  ‘endocrine 
resistance’, an arbitrary threshold of 2 years was defined to dis-
tinguish between primary and secondary resistance, although 
most agreed that endocrine resistance develops in a continuous 
manner rather than sporadically after a distinct time interval. 
However, it was agreed that a pragmatic definition should be 
sought.
A special issue at the ABC2 Meeting was the integration of 
a patient’s advocacy committee with specifically dedicated 
workshops. The results were then reported during the consen-
sus discussion. Proposals of the patient’s advocacy committee 
were included as new statements that referred to the need for a 
comprehensive and understandable communication between 
care givers and patients with advanced breast cancer, the need 
for including a breast care nurse in the multidisciplinary team, 
and the need for protocolling the therapy side effects in a clear 
and standardized manner.
Modifications of Statements of the ABC1 2011
Initially, it was agreed that age should not be used as a sole 
criterion for treatment decisions (to withhold or to administer 
more aggressive therapies). With regard to ER-positive/HER-
2-negative MBC, the statements on treatment with everoli-
mus were updated, acknowledging the substantially positive 
effect on the progression-free survival when balanced with 
potential toxicities occurring in some patients. Statements 
 regarding HER2-positive MBC were also revised in the light 
of the recent data on the efficacy of the third generation of 
anti-HER2 drugs (pertuzumab, T-DM1) and the value of dif-
ferent combinations (e.g. capecitabine-lapatinib, trastuzumab-
chemotherapy combinations, and trastuzumab-lapatinib).
Finally, the type and sequence of second-line endocrine 
therapies and chemotherapies were discussed. Considering 
the multiple types, effects and duration of pretreatment, a 
 single general recommendation no longer seems reasonable. 
Special attention was given to the treatment of male MBC 
 regarding the question of whether sole aromatase inhibition is 
sufficient. The majority felt that the available data do not sup-
port the omission of gonadotropin suppression using GnRH 
agonists if aromatase inhibitors were used.
The slides of the ABC1 consensus 2011 that were not mod-
ified and not discussed in the current meeting will be placed 
into the supplementary material of the final publication of the 
ABC2 consensus statements, expected in spring 2014 in ‘The 
Breast’. We can congratulate the organizers, particularly 
 Fatima Cardoso (Lisbon), Eric Winer (Boston), Alberto 
Costa (Milan), and Larry Norton (New York), for this impor-
tant initiative and the organization of these fruitful meetings 
on advanced breast cancer, and we are awaiting the next 
meeting, ABC3, planned in 2015.
Table 1. ABC 2 consensus panellists
Matti S. Aapro, CH Clifford A. Hudis, US
Fabrice André, FR Bella Kaufman, IL
Carlos H. Barrios, BR Ian E. Krop, US
Jonas Bergh, SE Nancy U. Lin, US
Elizabeth Bergsten Nordström, IT Musa Mayer, US
Laura Biganzoli, IT Sofia D. Merjaver, US
Kimberley L. Blackwell, US Larry Norton, US
Fatima Cardoso, PT Olivia Pagani, CH
Maria João Cardoso, PT Ann H. Partridge, US
Alberto Costa, CH/IT Frédérique Penault-Llorca, FR
Tanja Cufer, SL Martine J. Piccart, BE 
Nagi S. El Saghir, LB Hope S. Rugo, US 
Lesley Fallowfield, UK Elzbieta Senkus-Konefka, PL
Doris Fenech, MT George W. Sledge, US
Prudence A. Francis, AU Christoph Thomssen, DE
Karen Gelmon, CA Laura van’t Veer, US
Sharon H. Giordano, US Conny Vrieling, CH
Joseph Gligorov, FR Nicola West, UK
Nadia Harbeck, DE Eric P. Winer, US
Nehmat Houssami, AU Binghe Xu, CN
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